Get started
Author

Melanie Frank

Observed names: M Frank, M. Frank
ORCID: 0000-0001-6294-2106
Observed ORCID: 0000-0001-6294-2106
OpenAlex ID: A5101534415
SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11)
2018 · Margitta Retz, Jens Bedke, et al. · European Journal of Cancer · 33
Routine treatment and outcome of breast cancer in younger versus elderly patients: results from the SENORA project of the prospective German TMK cohort study
2017 · the TMK-Group (Tumour Registry Breast Cancer), Thomas Fietz, et al. · Breast Cancer Research and Treatment · 24
PDF
Oxaliplatin-based first-line chemotherapy is associated with improved overall survival compared to first-line treatment with irinotecan-based chemotherapy in patients with metastatic colorectal cancer – Results from a prospective cohort study
2015 · Norbert Marschner, Dirk Arnold, et al. · Clinical Epidemiology · 21
PDF
Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of metastatic renal cell carcinoma (SWITCH-II)
2017 · M. Retz, J. Bedke, et al. · Annals of Oncology · 20
PDF
Bendamustine as first-line treatment in patients with advanced indolent non-Hodgkin lymphoma and mantle cell lymphoma in German routine clinical practice
2015 · M. Becker, B. Tschechne, et al. · Annals of Hematology · 11
PDF
Antianemic Treatment of Cancer Patients in German Routine Practice: Data from a Prospective Cohort Study—The Tumor Anemia Registry
2016 · Tilman Steinmetz, Jan Schröder, et al. · Anemia · 10
PDF
Effectiveness, safety and quality of life of trifluridine/tipiracil in pretreated patients with metastatic colorectal cancer: Real‐world data from the noninterventional TACTIC study in Germany
2023 · Hendrik Kröning, Thomas Göhler, et al. · International Journal of Cancer · 9
PDF
Development and validation of a novel prognostic score to predict survival in patients with metastatic colorectal cancer: the metastatic colorectal cancer score ( mCCS )
2019 · N. Marschner, M. Frank, et al. · Colorectal Disease · 7
PDF
Adjuvant chemotherapeutic treatment of 1650 patients with early breast cancer in routine care in Germany: data from the prospective TMK cohort study
2017 · The TMK-Group (Tumour Registry Breast Cancer), Steffen Dörfel, et al. · Breast Cancer · 5
PDF
Quantifying bias due to missing data in quality of life surveys of advanced-stage cancer patients
2024 · Nina Haug, Martina Jänicke, et al. · Quality of Life Research · 4
PERFORM: A Non-Interventional Study Assessing The Patients' Treatment Starting With 1L Palbociclib in HR+/HER2- ABC
2022 · Michael Patrick Lux, Eva Diana Runkel, et al. · Future Oncology · 4
Individually compounded multi-chamber vs. standardized parenteral nutrition bags in solid tumors–A randomized clinical trial (IKF-010)
2025 · Thorsten Oliver Goetze, Ralf-Dieter Hofheinz, et al. · Clinical Nutrition ESPEN · 3
Prognostic factors for overall survival of patients with advanced renal cell carcinoma – data from the German prospective RCC-Registry
2017 · P.J. Goebell, L. Müller, et al. · Annals of Oncology · 2
31P Molecular testing, treatment and outcome of patients with advanced solid tumors harboring a NTRK1, NTRK2 or NTRK3 gene fusion: Study design and first results of the REALTRK registry
2022 · C. Vannier, A. Völkel, et al. · Annals of Oncology · 1
Treatment reality and outcome data of patients with advanced papillary renal cell carcinoma: Data from the German prospective RCC-Registry
2017 · M. Staehler, L. Müller, et al. · Annals of Oncology · 1
Therapie neuroendokriner Tumoren des Gastrointestinaltraktes
2008 · A. Sprenger, M. Frank, et al. · Chirurgische Gastroenterologie · 1
Versorgungsrealität in Deutschland und Österreich – Zweite Interimsanalyse der nicht-Interventionellen Studie PERFORM für PatientInnen mit HR+/HER2- fortgeschrittenem Brustkrebs, die in der Erstlinie mit endokrin-basierter Palbociclib-Therapie behandelt werden
2023 · C F Singer, J Radosa, et al. · Geburtshilfe und Frauenheilkunde
P-55 Efficacy and safety data from patients with pre-treated metastatic colorectal cancer receiving trifluridine/tipiracil: Real-world data from the non-interventional TACTIC study
2022 · D. Semsek, H. Kröning, et al. · Annals of Oncology
First interim results of the PERFORM study evaluating palbociclib in combination with endocrine therapy for HR+/HER2- advanced breast cancer
2022 · M.P. Lux, J. Wilke, et al. · Senologie - Zeitschrift für Mammadiagnostik und -therapie
PERFORM: An epidemiological, prospective cohort study for patients with HR+/HER2- advanced breast cancer treated 1st-line with an endocrine-based palbociclib combination therapy in real world in Germany and Austria
2021 · MP Lux, T Resch, et al. · Senologie - Zeitschrift für Mammadiagnostik und -therapie
Prognostic factors for overall survival of patients with advanced renal cell carcinoma - data from the German prospective RCC-Registry
2017 · P. J. Göbell, L. Müller, et al.
Treatment reality and outcome data of patients with advanced papillary renal cell carcinoma - data from the German prospective RCC-Registry
2017 · Michael S. Stahler, P. J. Göbell, et al.
Preliminary results of efficacy and tolerability of first-line bevacizumab in combination with carboplatin/paclitaxel in patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer in clinical practice - a German cohort study.
2015 · Alexander Mustea, Sven Mahner, et al. · Journal of Clinical Oncology
Exploring the cost-effectiveness of targeted therapy with cetuximab vs bevacizumab in Germany in patients with KRAS wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver
2011 · M. Frank, Christian Asseburg, et al.
Works count: 24
Citation count: 156
H-index: 7
I10-index: 6
Year
Topic
Type